Expanded Canadian approval for Qiagen's HPV test
This article was originally published in Clinica
Executive Summary
The digene human papillomavirus (HPV) test platform developed by Qiagen may now be used in Canada to screen women for cervical cancer, with or without the Pap smear test. The digene HC2 High-Risk HPV DNA test was previously approved in Canada for co-testing with the Pap test; this label update now enables primary, front-line HPV screening. Health Canada has also approved updated labelling for the Venlo, Netherlands-based firm's HPV test, expanding approval to cover screening BD SurePath specimens. Testing with Qiagen's digene HPV Test can now be performed in labs on three different specimen collection vials: BD SurePath, Hologic PreservCty and Qiagen's digene Specimen Transport Medium.